Novartis Meningococcal Serogroup B Recombinant Vaccine
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Novartis Meningococcal Serogroup B Recombinant Vaccine, covering 2015-03-06 to 2015-03-06. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. [Phase 3]